



MSF AT THE 48TH UNION WORLD CONFERENCE ON LUNG HEALTH Guadalajara, Mexico | 11 – 14 October 2017

MSF EVENTS

[endTB Symposium: Accelerating TB elimination through access to bedaquiline and delamanid](#) **October 12**
Hall 10 - Jalisco Hall 14:00 – 15:30

The symposium will provide an update on the UNITAID-funded endTB initiative and findings, including culture conversion and reversion and adverse events for the 600 people who have received bedaquiline or delamanid.

[Community space \(Encuentro\) session: Five urgent improvements to DR-TB treatment](#) **October 13**
Foro - Encuentro Expo 17:00 – 18:00

Evidence for treatment with newer DR-TB drugs, shorter treatment regimens, ambulatory care instead of hospitalisation, and fast-track registration of new drugs.

[MSF Symposium: Reducing catastrophic costs for people with TB through patient-centred care](#) **October 14**
Hall 10 - Jalisco Hall 10:30 – 12:00

Session will analyse the barriers to reducing costs and burden for people with drug-resistant TB including: decentralised and ambulatory treatment, shorter treatment and newer drugs to reduce toxicity, and interventions to reduce out-of-pocket costs of treatment.

ORAL ABSTRACTS

TB POLICIES

[Many national TB programmes are out of step with international recommendations for testing, treatment and prevention: results of a 30 country survey](#) **October 12**
Hall 2 – Events Ballroom 16:00 – 17:30
SOA-365-12

[Setting up an active pharmacovigilance system for the endTB project](#) **October 13**
Hall 13 - Jalisco Hall 10:30 – 12:00
OA-160-13

DRUG-RESISTANT TB TREATMENT

[Early safety and efficacy of bedaquiline and delamanid combination for drug-resistant TB in Armenia, India and South Africa](#) **October 13**
Plenary Hall 10:30-12:00
OA-2905-13

[Adverse events over 6 months with delamanid in a programmatic setting in Khayelitsha, South Africa](#) **October 13**
Hall 13 – Jalisco Hall 10:30 – 12:00
OA-162-13

[Safety of multidrug resistant tuberculosis treatment amongst patients receiving bedaquiline in a compassionate use program in Armenia and Georgia](#) **October 13**
Hall 13 – Jalisco Hall 10:30 – 12:00
OA-163-13

[Risk factors for developing hypothyroidism among MDR-TB patients receiving Eto and/or PAS in Maputo, Mozambique](#) **October 13**
Hall 13 – Jalisco Hall 10:30 – 12:00
OA-164-13

[Psychiatric comorbidity among drug-resistant tuberculosis patients](#) **October 13**
Hall 13 – Jalisco Hall 10:30 – 12:00
OA-167-13

[Culture conversion and reversion of multidrug resistant tuberculosis patients receiving bedaquiline in a compassionate use program in Armenia and Georgia](#) **October 13**
Hall 13 – Jalisco Hall 16:00 – 17:30
OA-188-13

[Bedaquiline- and linezolid-based regimens for fluoroquinolone-resistant MDR-TB: how much better is it?](#) **October 13**
Hall 13 – Jalisco Hall 16:00 – 17:30
OA-190-13

[Outcomes of multidrug resistant tuberculosis patients receiving Bedaquiline in a compassionate use program in Armenia and Georgia](#) **October 13**
Hall 13 – Jalisco Hall 16:00 – 17:30
OA-192-13

[Delamanid for rifampicin-resistant tuberculosis: an observational cohort study from Khayelitsha, South Africa](#) **October 13**
Hall 13 – Jalisco Hall 16:00 – 17:30
OA-193-13

TB DIAGNOSTICS

[Value of determine-TB LAM test as screening test and as diagnostic tool for tuberculosis diagnosis in HIV positive adults](#) **October 13**
Hall 8 – Events Ballroom 10:30 – 12:00
SOA-402-13

[Cost-effectiveness of including determine TB-LAM test to diagnose tuberculosis in HIV-positive symptomatic patients](#) **October 14**
Hall 4 – Events Ballroom 10:30 – 12:00
SOA-443-14

LATENT TB INFECTION

[Incidence of latent tuberculosis infection and tuberculosis disease after 24 months follow-up in paediatric contacts of drug-resistant tuberculosis patients in Armenia](#) **October 12**
Hall 13 - Jalisco Hall 14:00 – 15:30
SOA-360-12

CO-INFECTIONS (HCV)

[High rates of active hepatitis C amongst multidrug resistant tuberculosis patients in Armenia](#) **October 12**
Hall 14 - Jalisco Hall 10:30 – 12:00
OA-125-12

POSTER PRESENTATIONS

All poster presentations take place in the Poster Area from 12:45 – 13:45 on the designated date

TB POLICIES

[Threats to affordable quality second-line TB drugs in Eastern Europe/Central Asia as the Global Fund shifts to national procurement](#) **October 14**
PD-893-14

DRUG-RESISTANT TB TREATMENT

[Introduction of a short standardized course of treatment for multidrug-resistant Tuberculosis in Mozambique: cohort description and early culture conversion in HIV-positive and HIV-negative patients](#) **October 12**
PD-537-12

[Outcomes and risk factors in a program treating MDR-TB in Swaziland for 2011-2013 cohorts](#) **October 12**
PD-547-12

<u>Drug induced hypothyroidism during treatment for multidrug resistant tuberculosis in Swaziland</u>	October 13 PD-685-13
<u>Lessons learned from the design, development, and deployment of endTB electronic medical record for MDR-TB across 16 countries</u>	October 13 PD-700-13
<u>Interim report on the use of a short, simplified regimen for the treatment of children with multidrug-resistant tuberculosis in Karakalpakstan, Uzbekistan</u>	October 13 PD-809-13
<u>Accelerating access to delamanid for rifampicin-resistant tuberculosis in Khayelitsha, South Africa</u>	October 14 PD-891-14
<u>The impact of pyrazinamide resistance upon the treatment outcome of patients with multidrug-resistant tuberculosis in Karakalpakstan, Uzbekistan</u>	October 14 PD-894-14

TB DIAGNOSTICS

<u>Evaluation of the OMNIgene® SPUTUM reagent for long term transportation of samples for Xpert testing in a high TB-HIV setting</u>	October 13 PD-837-13
<u>Does the determine-TB LAM test have a potential value in tuberculosis diagnosis among severely acute malnourished (SAM) children?</u>	October 14 PD-924-14

LATENT TB INFECTION

<u>Discordances between TST and IGRA to detect latent tuberculosis infection in paediatric contacts of drug-resistant tuberculosis patients</u>	October 14 PD-944-14
---	--------------------------------

REPORTS

For MSF TB reports, including OUT OF STEP go to: <https://www.msfacecess.org/tb>

- Out of Step 2017: www.msfacecess.org/outofstep2017
- DR-TB Drugs Under the Microscope, 4th Edition: www.msfacecess.org/utm2016